![]() |
Code of Federal Regulations (Last Updated: July 5, 2024) |
![]() |
Title 21 - Food and Drugs |
![]() |
Chapter I - Food and Drug Administration, Department of Health and Human Services |
![]() |
SubChapter D - Drugs for Human Use |
![]() |
Part 314 - Applications for FDA Approval to Market a New Drug |
![]() |
Subpart B - Applications |
§ 314.50 - Content and format of an NDA. |
§ 314.52 - Notice of certification of invalidity, unenforceability, or noninfringement of a patent. |
§ 314.53 - Submission of patent information. |
§ 314.54 - Procedure for submission of a 505(b)(2) application requiring investigations for approval of a new indication for, or other change from, a listed drug. |
§ 314.55 - Pediatric use information. |
§ 314.60 - Amendments to an unapproved NDA, supplement, or resubmission. |
§ 314.65 - Withdrawal by the applicant of an unapproved application. |
§ 314.70 - Supplements and other changes to an approved NDA. |
§ 314.71 - Procedures for submission of a supplement to an approved application. |
§ 314.72 - Change in ownership of an application. |
§ 314.80 - Postmarketing reporting of adverse drug experiences. |
§ 314.81 - Other postmarketing reports. |
§ 314.90 - Waivers. |
§ 314.91 - Obtaining a reduction in the discontinuance notification period. |